Correction to: Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands (Cardiovascular Diabetology, (2023), 22, 1, (328), 10.1186/s12933-023-02053-6)

In the original publication of this article [1], the authors identified typographical errors in Tables 2 and 7. In Table 2, the transition probability from CKD1/2 to CKD4 should be “0.0036” instead of “0.36”. In Table 7, the total indirect costs “€111,706 and €12,4069” was incorrect and should have been “€11,706 and €12,406”, though the difference between the two values remains correct. These corrections do not affect the methodology, results, or conclusion section. Transition probabilities: CKD progression and first modelled CV event and OHE probabilities [13] CKD1/2 CKD3 CKD4 CKD5 w/o dialysis Dialysis (acute) Dialysis (post-acute) Kidney Transplant (acute) Kidney Transplant (post-acute) Transition probabilities CKD progression for patients receiving SoC^a [13] CKD1/2 0.6696 0.3268 0.0036 CKD3 0.0350 0.8705 0.0931 0.0011 0.0002 CKD4 0.0012 0.1400 0.8043 0.0448 0.0096 CKD 5 w/o dialysis 0.0135 0.0889 0.7143 0.1779 0.0054 Dialysis (acute) 1.0000 Dialysis (post-acute) 0.9921 0.0079 Kidney transplant (acute) 1.0000 Kidney transplant (post-acute) 1.0000 CKD1/2 CKD3 CKD4 CKD5 w/o dialysis Dialysis (acute) Dialysis (post-acute) Kidney Transplant (acute) Kidney Transplant (post-acute) Transition probabilities CKD progression for patients receiving SoC and Finerenone^a [13] CKD1/2 0.6305 0.3665 0.0030 CKD3 0.0269 0.8770 0.0949 0.0009 0.0002 CKD4 0.0016 0.1548 0.7982 0.0371 0.0083 CKD 5 w/o dialysis 0.0075 0.1267 0.7045 0.1559 0.0054 Dialysis (acute) 1.0000 Dialysis (post-acute) 0.9921 0.0079 Kidney transplant (acute) 1.0000 Kidney transplant (post-acute) 1.0000 CKD1/2 CKD3 CKD4 CKD5 w/o dialysis Dialysis (acute) Dialysis (post-acute) Kidney Transplant (acute) Kidney Transplant (post-acute) Transition probabilities for CV events per CKD stage [13] Any CV event probability^b 0.0119 0.0127 0.0157 0.0208 0.0208 0.0208 0.0157 0.0157 CV death 0.0062 0.0052 0.0081 0.0157 0.0191 0.0191 0.0081 0.0081 Renal death 0.000 0.000 0.000 0.0001 0.000 0.000 0.000 0.000 Probabilities of OHEs [13] Subsequent CV event – 7.32% Hyperkalaemia leading to hospitalization 0.07% 0.38% Hyperkalaemia not leading to hospitalization 1.63% 2.35% New onset of atrial fibrillation 0.35% 2.16% CKD chronic kidney disease, CV cardiovascular, eGFR estimated glomerular filtration rate, HR hazard ratio, MI Myocardial infarction, OHE Other health events, SoC standard of care, w/o without ^a The transition probabilities of CKD progression were based on end points that were measured every four months in the FIDELIO-DKD trial with a median follow-up of 2.6 years. For patients that received finerenone, the probability of transitioning to CKD 5 was adjusted with the HR for the onset of eGFR decrease < 15 mL/min/1.73 m² sustained over at least four weeks, and the probability of transition to dialysis was adjusted with the HR for progression to dialysis. ^b CV events included non-fatal MI, stroke, or hospitalization for heart failure Costs, QALYs, and ICER per patient over a lifetime for finerenone + SoC and SoC Finerenone + SoC SoC Difference Costs within the healthcare system Medication costs €10,098 €6,554 €3,545 CKD treatment €4272 €4,125 €148 Dialysis €57,650 €65,584 − €7,935 Transplant €2262 €2,125 − €275 First CV event costs €5843 €6,134 − €291 Subsequent CV event €1528 €1,633 − €105 Hyperkalaemia leading to hospitalization €159 €88 €70 Hyperkalaemia not leading to hospitalization €192 €126 €66 New onset of atrial fibrillation €168 €198 − €30 Indirect costs for patients and caregivers €11,076 €12,406 − €1,329 Total costs (healthcare perspective) €82,172 €86,978 − €4,708 Total costs (societal perspective) €93,248 €99,384 − €6,136 Total effects (life-years without CV) 7.43 7.13 0.30 Total effects (life-years without RRT) 8.65 8.34 0.31 Total effects (life-years) 9.40 9.18 0.22 Total effects (QALY) 7.05 6.85 0.20